Tumor Vasculature Remains Stable Through Progression of Ovarian Cancer


The intratumoral vasculature of high-grade serous ovarian cancer does not appear to undergo significant changes during disease progression.

The intratumoral vasculature of high-grade serous ovarian cancer does not appear to undergo significant changes during disease progression, according to a new study. The measures of angiogenesis studied were not associated with overall survival.

“After decades of paralysis in primary ovarian cancer first-line chemotherapy treatment, incorporation of bevacizumab in the upfront regimen for advanced newly diagnosed disease has changed the ‘standard of care paradigm’ of advanced primary ovarian cancer,” wrote study authors led by Ilary Ruscito, MD, of Sapienza University of Rome in Italy. “Thus, understanding changes in the vasculature or identification of prognostic biomarkers of response to vasculature targeting is needed.” There are no current biomarkers to help tailor bevacizumab treatment in ovarian cancer patients.

The new study examined tumor microvessel density (MVD) and VEGF-A expression in a cohort of 222 paired samples of primary and recurrent ovarian cancer. MVD was measured using immunohistochemistry measurement of CD31, an angiogenesis-associated biomarker. The results were published in the British Journal of Cancer.

A total of 84 of the 111 primary ovarian cancer samples (75.7%) had high intratumoral MVD expression, and 23 samples (20.7%) had VEGF-A expression. In the 111 recurrent samples, 57 were MVDhigh (51.4%) and 23 were VEGF-positive (20.7%).

There were 22 primary samples that had both high MVD expression and expressed VEGF-A (19.8%); for recurrent samples, this was seen in 9 patients (8.1%; P = .02).

A pairwise analysis showed there was no significant change from primary to recurrent ovarian cancer with regard to MVD (P = .935) or VEGF-A expression (P = .121).

Samples that were MVDhigh were associated with higher CD3-positive (P = .029) and CD8-positive (P = .013) intratumoral effector tumor-infiltrating lymphocytes. In contrast, VEGF-positive samples were frequently seen in BRCA-mutated tumors (P = .019).

Primary ovarian cancers that were MVDhigh or VEGF-positive were found to be significantly associated with improved overall survival, but this association did not remain upon a multivariable analysis.

“Future study on a larger population with known BRCA status, who has been subjected to bevacizumab-based first-line chemotherapy, is warranted to clarify the role of MVD and VEGF in predicting bevacizumab response in both BRCA wild-type and BRCA-mutated high-grade serous ovarian cancer patients,” the authors concluded.

Related Videos
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Related Content